Transplant-Ineligible NDMM: Updates from CEPHEUS and IMROZ at ASH 2024
Panelists discuss recent data updates on transplant-ineligible and deferred newly diagnosed multiple myeloma (NDMM), including findings from the CEPHEUS and IMROZ studies, and explore the clinical significance of minimal residual disease negativity as a prognostic and actionable factor in treatment decision-making for NDMM.
EP: 1.Highlights from ASH 2024: Optimizing Frontline Therapy in Transplant-Eligible MM
EP: 2.Tailoring Induction Therapy in Newly Diagnosed Transplant-Eligible MM: Key Considerations
EP: 3.AURIGA Trial Highlights: Daratumumab + Lenalidomide Maintenance in Newly Diagnosed MM
EP: 4.Transplant-Ineligible NDMM: Updates from CEPHEUS and IMROZ at ASH 2024
Video content above is prompted by the following:
- Please comment on recent data updates for transplant-ineligible/deferred newly diagnosed multiple myeloma (NDMM):
- CEPHEUS study, SubQ Dara-VRd vs VRd in transplant-ineligible NDMM
- IMROZ study, Isa-VRd vs VRd in TIE/deferred NDMM
- What is the clinical significance of minimal residual disease (MRD) negativity as a clinical outcome? How do you interpret and integrate MRD negativity into your clinical decision-making? Beyond its prognostic value, what actionable insights does MRD provide in guiding treatment strategies and patient management?
- Please highlight key insights from MRD analyses in NDMM presented at ASH 2024.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
